Astellas and Medivation develop prostate cancer candidate
Astellas Pharma and Medivation (drugs for serious diseases) have entered into a worldwide co-development and co-commercialization agreement for the latter's MDV3100, a Phase III oral anti-androgen for castration-resistant prostate cancer.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.